(CercleFinance.com) – Lysogene sells nearly 3% on Thursday on the Paris Bourse after the announcement of the termination of the licensing agreements signed with Sarepta for the LYS-SAF302 program, an experimental drug against type IIIA mucopolysaccharidosis.
The biopharmaceutical company explains that the termination follows unsuccessful discussions regarding the transfer to Lysogene of the responsibility for the production of the commercial product on a global level.
The termination of these agreements will allow the recovery of rights relating to commercialization and development in the United States and in other territories outside of Europe.
As such, the company will receive compensation for the reimbursement of certain costs associated with the termination.
As a reminder, LYS-SAF302 has obtained treatment status for a rare pediatric disease in the United States and the European Union. It has also received ‘fast track’ and orphan drug designations in the United States.
Recruitment and treatment for the global Phase 2/3 clinical trial is fully completed and all patients are being followed according to study protocol.
Analysis of the study’s primary endpoint data is scheduled for mid-2022, as initially anticipated.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
